Literature DB >> 18475076

Review of current guidelines related to the diagnosis and treatment of rhinosinusitis.

Aaron N Pearlman1, David B Conley.   

Abstract

PURPOSE OF REVIEW: Rhinosinusitis is one of the most common medical complaints, affecting nearly 31 million US citizens annually. Multiple medical professionals including emergency medicine, internal medicine, allergy, and otolaryngology treat rhinosinusitis, resulting in high-practice variability. This review will discuss recommendations of the 2007 American Academy of Otolaryngology - Head and Neck Surgery's multispecialty panel on evidence based clinical practice guidelines for diagnosis and treatment of rhinosinusitis. RECENT
FINDINGS: The task force for recommendations defines rhinosinusitis as follows: acute bacterial, viral, chronic, or recurrent acute rhinosinusitis. For acute rhinosinusitis three symptoms are required: purulent nasal discharge with nasal obstruction and/or facial pain-pressure-fullness lasting between 10 days and 4 weeks. For viral rhinosinusitis, imaging is not recommended and treatment is symptomatic. For acute bacterial rhinosinusitis in an otherwise healthy patient, symptomatic relief is recommended including pain control. Amoxicillin is the first-line antibiotic of choice if needed. Radiographic imaging should be considered if an infectious complication is suspected. Chronic rhinosinusitis is likely when symptoms persist for greater than 12 weeks, with computed tomography being the gold standard for diagnostic testing. Nasal endoscopy and allergy/immune testing are also considered.
SUMMARY: Accurate diagnosis of rhinosinusitis with recommended treatments should standardize management. However, these recommendations are guidelines and the clinician's judgment is highly important.

Entities:  

Mesh:

Year:  2008        PMID: 18475076     DOI: 10.1097/MOO.0b013e3282fdcc9a

Source DB:  PubMed          Journal:  Curr Opin Otolaryngol Head Neck Surg        ISSN: 1068-9508            Impact factor:   2.064


  16 in total

1.  [Rhinosinusitis guidelines--unabridged version: S2 guidelines from the German Society of Otorhinolaryngology, Head and Neck Surgery].

Authors:  B A Stuck; C Bachert; P Federspil; W Hosemann; L Klimek; R Mösges; O Pfaar; C Rudack; H Sitter; M Wagenmann; R Weber; K Hörmann
Journal:  HNO       Date:  2012-02       Impact factor: 1.284

2.  The contribution of flexible endoscopy for diagnosis of acute bacterial rhinosinusitis.

Authors:  Gilead Berger; Rachel L Berger
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-07-08       Impact factor: 2.503

Review 3.  Comprehensive review on endonasal endoscopic sinus surgery.

Authors:  Rainer K Weber; Werner Hosemann
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2015-12-22

4.  Increased expression of the chemokine CCL23 in eosinophilic chronic rhinosinusitis with nasal polyps.

Authors:  Julie A Poposki; Ashraf Uzzaman; Deepti R Nagarkar; Regina T Chustz; Anju T Peters; Lydia A Suh; Roderick Carter; James Norton; Kathleen E Harris; Leslie C Grammer; Bruce K Tan; Rakesh K Chandra; David B Conley; Robert C Kern; Robert P Schleimer; Atsushi Kato
Journal:  J Allergy Clin Immunol       Date:  2011-04-17       Impact factor: 10.793

5.  Increased expression of factor XIII-A in patients with chronic rhinosinusitis with nasal polyps.

Authors:  Tetsuji Takabayashi; Atsushi Kato; Anju T Peters; Kathryn E Hulse; Lydia A Suh; Roderick Carter; James Norton; Leslie C Grammer; Bruce K Tan; Rakesh K Chandra; David B Conley; Robert C Kern; Shigeharu Fujieda; Robert P Schleimer
Journal:  J Allergy Clin Immunol       Date:  2013-03-28       Impact factor: 10.793

6.  Increased thrombin-activatable fibrinolysis inhibitor levels in patients with chronic rhinosinusitis with nasal polyps.

Authors:  Yoshimasa Imoto; Atsushi Kato; Tetsuji Takabayashi; Whitney Stevens; James E Norton; Lydia A Suh; Roderick G Carter; Ava R Weibman; Kathryn E Hulse; Kathleen E Harris; Anju T Peters; Leslie C Grammer; Bruce K Tan; Kevin Welch; Stephanie Shintani-Smith; David B Conley; Robert C Kern; Shigeharu Fujieda; Robert P Schleimer
Journal:  J Allergy Clin Immunol       Date:  2019-09-25       Impact factor: 10.793

7.  Short-chain fatty acids induce tissue plasminogen activator in airway epithelial cells via GPR41&43.

Authors:  Y Imoto; A Kato; T Takabayashi; M Sakashita; J E Norton; L A Suh; R G Carter; A R Weibman; K E Hulse; W Stevens; K E Harris; A T Peters; L C Grammer; B K Tan; K Welch; D B Conley; R C Kern; S Fujieda; R P Schleimer
Journal:  Clin Exp Allergy       Date:  2018-03-24       Impact factor: 5.018

8.  Increased expression of the epithelial anion transporter pendrin/SLC26A4 in nasal polyps of patients with chronic rhinosinusitis.

Authors:  Sudarshan Seshadri; Xiang Lu; Matthew R Purkey; Tetsuya Homma; Andrew Wonho Choi; Roderick Carter; Lydia Suh; James Norton; Kathleen E Harris; David B Conley; Atsushi Kato; Pedro C Avila; Barbara Czarnocka; Peter A Kopp; Anju T Peters; Leslie C Grammer; Rakesh K Chandra; Bruce K Tan; Zheng Liu; Robert C Kern; Robert P Schleimer
Journal:  J Allergy Clin Immunol       Date:  2015-07-02       Impact factor: 10.793

9.  15-Lipoxygenase 1 in nasal polyps promotes CCL26/eotaxin 3 expression through extracellular signal-regulated kinase activation.

Authors:  Zhipeng Li; Ming Zeng; Yanhan Deng; Jinming Zhao; Xiuxia Zhou; John B Trudeau; Ezequiel Goldschmidt; John A Moore; Hongwei Chu; Weitian Zhang; Shankai Yin; Zheng Liu; Y Peter Di; Stella E Lee; Sally E Wenzel
Journal:  J Allergy Clin Immunol       Date:  2019-07-11       Impact factor: 10.793

10.  Excessive fibrin deposition in nasal polyps caused by fibrinolytic impairment through reduction of tissue plasminogen activator expression.

Authors:  Tetsuji Takabayashi; Atsushi Kato; Anju T Peters; Kathryn E Hulse; Lydia A Suh; Roderick Carter; James Norton; Leslie C Grammer; Seong H Cho; Bruce K Tan; Rakesh K Chandra; David B Conley; Robert C Kern; Shigeharu Fujieda; Robert P Schleimer
Journal:  Am J Respir Crit Care Med       Date:  2012-11-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.